## Protocol Section
### Identification Module
**NCT ID:** NCT05119179

**Brief Title:** Pharmacogenetics of the Response to GLP-1 in Mexican-Americans With Prediabetes

**Official Title:** Pharmacogenetics of the Response to GLP-1 in Mexican-Americans With Prediabetes

#### Organization Study ID Info
**ID:** HSC-MS-21-0297
#### Organization
**Class:** OTHER
**Full Name:** The University of Texas Health Science Center, Houston
### Status Module
#### Completion Date
**Date:** 2026-07

**Type:** ESTIMATED

#### Expanded Access Info
#### Last Update Post Date
**Date:** 2023-06-12

**Type:** ACTUAL

**Last Update Submit Date:** 2023-06-08

**Overall Status:** RECRUITING

#### Primary Completion Date
**Date:** 2025-11

**Type:** ESTIMATED

#### Start Date
**Date:** 2021-11-22

**Type:** ACTUAL

**Status Verified Date:** 2023-06

#### Study First Post Date
**Date:** 2021-11-15
**Type:** ACTUAL
**Study First Submit Date:** 2021-08-05
**Study First Submit QC Date:** 2021-11-01
### Sponsor Collaborators Module

#### Collaborators

**Class:** OTHER

**Name:** Vanderbilt University Medical Center

#### Lead Sponsor

**Class:** OTHER

**Name:** The University of Texas Health Science Center, Houston

#### Responsible Party

**Investigator Affiliation:** The University of Texas Health Science Center, Houston

**Investigator Full Name:** Absalon D Gutierrez

**Investigator Title:** Associate Professor of Medicine

**Type:** PRINCIPAL_INVESTIGATOR

### Oversight Module

**Is FDA Regulated Device:** False

**Is FDA Regulated Drug:** True

**Oversight Has DMC:** True

### Description Module

**Brief Summary:** This project uses both transcriptomic- and genomic-level data to identify mechanisms of individual responses to glucagon-like peptide-1 (GLP-1) in Mexican-Americans with prediabetes. The GLP-1 hormone is essential for glucose reduction, weight loss, cardiovascular risk reduction, and renal protection. Newly discovered mechanisms will illuminate causal links between disease genotype and phenotype, which may ultimately guide personalized therapeutic approaches for type 2 diabetes, prediabetes, obesity, cardiovascular disease, renal disease, and other related diseases.

**Detailed Description:** This clinical trial will uncover new mechanisms of inter-individual responses to endogenous and exogenous glucagon-like peptide-1 (GLP-1) in Hispanics/Latinos (H/Ls) with prediabetes. The results move the management of prediabetes, type 2 diabetes mellitus (T2DM), and relevant metabolic diseases to a more individualized approach in an understudied and at-risk population. Few options exist for prediabetes treatment, and the current pharmaceutical management of T2DM does not predict drug treatment failures, nor differences in individual treatment responses and adverse effects. A precise, genetics-based approach will provide superior therapeutic management for patients. GLP-1-based therapies reduce blood glucose, promote weight loss, decrease cardiovascular events, and improve renal function. Prior genetic studies, most done in Caucasians, identified associations between genetic variants and decreased GLP-1-induced insulin secretion, in an effort to guide individualized treatment. However, these associations do not provide a clear mechanistic relationship between genotype and phenotype. Transcriptomic analyses will uncover many of these mechanisms. Here, we propose to 1) test the association of single nucleotide polymorphisms (SNPs) that regulate expression (eQTLs) of 11 candidate genes in a range of relevant metabolic tissues with differential GLP-1 response, 2) perform RNA sequencing before and after treatment to identify eQTLs in blood that predict response to GLP-1 therapy and develop risk-based prediction models in H/Ls, and 3) determine the effects of genetic regulation of candidate genes and newly discovered eQTLs phenome-wide in a large existing biobank, BioVU. For aims 1 and 2, responses will be measured in 300 study subjects with prediabetes recruited from an established Mexican-American cohort via the oral minimal model method, before and after GLP-1 therapy, quantifying GLP-1 hormone efficacy and GLP-1-induced pancreatic beta cell insulin release and peripheral insulin sensitivity. Procedures include serial measurements of plasma glucose, insulin, C-peptide, and GLP-1, and peripheral blood collection for RNA sequencing. Our central hypotheses are: (1) metabolic tissue-based eQTLs of GLP-1-associated genes will be associated with physiological response to endogenous and exogenous GLP-1,(2) identification of eQTLs associated with GLP-1 treatment-induced changes in whole blood will identify new gene targets, and (3) this data will lead to the creation of eQTL-based prediction models for related diseases. The study is innovative because it uses a novel combination of eQTL analysis and oral minimal model to assess GLP-1 response, examines a population highly underrepresented in pharmacogenomic studies, and utilizes novel statistical methods and applications to study gene expression. The significance of this newly acquired mechanistic information will ultimately guide precision therapeutic regimens for diabetes prevention and treatment, weight loss, cardiovascular risk reduction, and related metabolic complications in an understudied population.

### Conditions Module

**Conditions:**

- PreDiabetes

**Keywords:**

- prediabetes

- Mexican-American

- GLP-1

- pharmacogenetics

- expression quantitative trait loci

### Design Module

#### Design Info

**Allocation:** NA

**Intervention Model:** SINGLE_GROUP

**Intervention Model Description:** Single center, before and after clinical trial

##### Masking Info

**Masking:** NONE

**Primary Purpose:** TREATMENT

#### Enrollment Info

**Count:** 300

**Type:** ESTIMATED

**Phases:**

- PHASE4

**Study Type:** INTERVENTIONAL

### Arms Interventions Module

#### Arm Group 1

**Description:** Semaglutide 0.25 mg subcutaneously weekly for 4 weeks, followed by semaglutide 0.5 mg subcutaneously weekly for 8 weeks.

**Intervention Names:**

- Drug: Semaglutide

**Label:** Semaglutide

**Type:** EXPERIMENTAL

### Interventions

#### Intervention 1

**Arm Group Labels:**

- Semaglutide

**Description:** Glucagon-like Peptide 1 Receptor Agonist

**Name:** Semaglutide

**Other Names:**

- Ozempic

**Type:** DRUG

### Outcomes Module

#### Primary Outcomes

**Description:** A rate which measures the ability of beta cells to secrete insulin

**Measure:** Mean change in beta cell responsivity

**Time Frame:** 12 weeks

**Description:** Measurement of the efficacy of insulin action at peripheral tissues

**Measure:** Insulin Sensitivity

**Time Frame:** 12 weeks

**Description:** Product of beta cell responsivity and insulin sensitivity (see above)

**Measure:** Disposition Index

**Time Frame:** 12 weeks

**Description:** Measurement of GLP-1 (glucagon-like peptide 1) hormonal efficacy in relationship to postprandial insulin secretion

**Measure:** GLP-1-Induced Potentiation

**Time Frame:** 12 weeks

**Description:** Comparison of GLP-1 AUC measurements before and after drug intervention

**Measure:** Mean change in GLP-1 Area Under the Curve (AUC)

**Time Frame:** 12 weeks

**Description:** eQTLs (expresion quantitative trait loci) are genes which affect the mRNA expression of another target gene.

**Measure:** Gene expression changes for minor variants of eQTLs for TCF7L2

**Time Frame:** 12 weeks

**Description:** eQTLs (expresion quantitative trait loci) are genes which affect the mRNA expression of another target gene.

**Measure:** Gene expression changes for minor variants of eQTLs for KCNQ1

**Time Frame:** 12 weeks

**Description:** eQTLs (expresion quantitative trait loci) are genes which affect the mRNA expression of another target gene.

**Measure:** Gene expression changes for minor variants of eQTLs for WFS1

**Time Frame:** 12 weeks

**Description:** eQTLs (expresion quantitative trait loci) are genes which affect the mRNA expression of another target gene.

**Measure:** Gene expression changes for minor variants of eQTLs for THADA

**Time Frame:** 12 weeks

**Description:** eQTLs (expresion quantitative trait loci) are genes which affect the mRNA expression of another target gene.

**Measure:** Gene expression changes for minor variants of eQTLs for CNR1

**Time Frame:** 12 weeks

**Description:** eQTLs (expresion quantitative trait loci) are genes which affect the mRNA expression of another target gene.

**Measure:** Gene expression changes for minor variants of eQTLs for CTRB1

**Time Frame:** 12 weeks

**Description:** eQTLs (expresion quantitative trait loci) are genes which affect the mRNA expression of another target gene.

**Measure:** Gene expression changes for minor variants of eQTLs for CTRB2

**Time Frame:** 12 weeks

**Description:** eQTLs (expresion quantitative trait loci) are genes which affect the mRNA expression of another target gene.

**Measure:** Gene expression changes for minor variants of eQTLs for GLP1R

**Time Frame:** 12 weeks

**Description:** eQTLs (expresion quantitative trait loci) are genes which affect the mRNA expression of another target gene.

**Measure:** Gene expression changes for minor variants of eQTLs for CHST3

**Time Frame:** 12 weeks

**Description:** eQTLs (expresion quantitative trait loci) are genes which affect the mRNA expression of another target gene.

**Measure:** Gene expression changes for minor variants of eQTLs for MTNR1B

**Time Frame:** 12 weeks

**Description:** eQTLs (expresion quantitative trait loci) are genes which affect the mRNA expression of another target gene.

**Measure:** Gene expression changes for minor variants of eQTLs for SORCS1

**Time Frame:** 12 weeks

**Description:** Study has statistical power to detect previously unidentified eQTLs

**Measure:** Previously unidentified cis-eQTLs associated with change in gene expression due to GLP-1 challenge

**Time Frame:** 12 weeks

#### Secondary Outcomes

**Description:** Comparison of glucose AUC measurements before and after drug intervention

**Measure:** Mean change in glucose Area Under the Curve (AUC)

**Time Frame:** 12 weeks

**Description:** Comparison of C-peptide AUC measurements before and after drug intervention

**Measure:** Mean change in C-peptide Area Under the Curve (AUC)

**Time Frame:** 12 weeks

**Description:** Change in hemoglobin A1C (measured once on each study day) before and after intervention

**Measure:** Change in hemoglobin A1C

**Time Frame:** 12 weeks

**Description:** Comparison of insulin AUC measurements before and after drug intervention

**Measure:** Mean change in insulin Area Under the Curve (AUC)

**Time Frame:** 12 weeks

**Description:** Create and apply eQTL-based prediction models to investigate the clinical consequences of variable GLP-1- induced gene expression changes (identified as above) in large electronic health records (EHRs), and use these models to predict disease risk phenome-wide.

**Measure:** Creation of eQTL-based disease prediction models

**Time Frame:** 5 years

**Description:** Creation of Polygenic prediction model using above data

**Measure:** Polygenic prediction model for GLP-1 therapy-associated outcomes

**Time Frame:** 5 years

### Eligibility Module

**Eligibility Criteria:** Inclusion criteria:

1. Men and women, ages 18 years and older
2. Diagnosis of Prediabetes - defined as either impaired fasting glucose (fasting glucose of 100-125 mg/dL), impaired glucose tolerance (2-hour postprandial blood glucose of 140-199 mg/dL after 75-gram oral glucose challenge), and/or a hemoglobin A1C ranging from 5.7% to 6.4%
3. High risk for progression to diabetes: defined as having at least one of the two following additional factors: Obesity (BMI ≥ 30 kg/m2) and/or metabolically unhealthy status. "Metabolically unhealthy status" is defined as at least two of the following: elevated blood pressure (SBP ≥ 130 mmHg and/or DBP ≥ 85 mmHg), elevated triglycerides ≥ 150 mg/dL, low HDL cholesterol (males \< 40 mg/dL; females \< 50 mg/dL), and elevated fasting glucose ≥ 100 mg/dL (Wu S et al., 2017).
4. Women of childbearing age must agree to use an acceptable method of pregnancy prevention (barrier methods, abstinence, hormonal contraception, intrauterine contraception, or surgical sterilization) for the duration of the study.
5. Patients must have the following laboratory values: Hematocrit ≥ 34 vol%, estimated glomerular filtration rate ≥ 60 mL/min per 1.73 m2, AST (SGOT) \< 2.5 times ULN, ALT (SGPT) \< 2.5 times ULN, alkaline phosphatase \< 2.5 times ULN

Exclusion Criteria:

1. History of Type 1 or Type 2 diabetes mellitus
2. Pregnant or breastfeeding women
3. Medications: metformin, DPP-4 inhibitors, GLP-1 receptor agonists, SGLT-2 inhibitors, thiazolidinediones, insulin, sulfonylureas, meglitinides, alpha-glucosidase inhibitors, and/or corticosteroids over the last 3 months.
4. Active malignancy
5. History of clinically significant cardiac, hepatic, pancreatic or renal disease.
6. History of any serious hypersensitivity reaction to the study medication (or any other incretin mimetic)
7. Prisoners or subjects who are involuntarily incarcerated
8. Prior history of pancreatitis, medullary thyroid cancer, or multiple endocrine neoplasia type 2 (MEN 2)
9. Family history of medullary thyroid cancer (a rare form of thyroid cancer) or MEN2. However, as many individuals may not be aware of the specific type of thyroid cancer, will also exclude any family history of thyroid cancer or MEN2.
10. Hospitalization for COVID-19 in last 3 months

**Minimum Age:** 18 Years

**Sex:** ALL

**Standard Ages:**

- ADULT

- OLDER_ADULT

### Contacts Locations Module

#### Central Contacts

**Contact 1:**

**Email:** Norma.P.PerezOlazaran@uth.tmc.edu

**Name:** Norma Perez-Olazaran

**Phone:** (956) 755-0695

**Role:** CONTACT

**Contact 2:**

**Email:** Rocio.D.Uribe@uth.tmc.edu

**Name:** Rocio Uribe

**Phone:** (956) 882-5165

**Role:** CONTACT

#### Locations

**Location 1:**

**City:** Brownsville

**Contacts:**

***Contact 1:***

- **Email:** Norma.P.PerezOlazaran@uth.tmc.edu

- **Name:** Norma Perez-Olazaran

- **Phone:** 956-755-0695

- **Role:** CONTACT

***Contact 2:***

- **Email:** Rocio.D.Uribe@uth.tmc.edu

- **Name:** Rocio Uribe

- **Phone:** (956) 882-5165

- **Role:** CONTACT

**Country:** United States

**Facility:** UTHealth Clinical Research Unit (CRU) at UT Brownsville

**State:** Texas

**Status:** RECRUITING

**Zip:** 78520

#### Overall Officials

**Official 1:**

**Affiliation:** The University of Texas Health Science Center, Houston

**Name:** Absalon D Gutierrez, MD

**Role:** PRINCIPAL_INVESTIGATOR

### IPD Sharing Statement Module

**IPD Sharing:** NO

## Derived Section

### Condition Browse Module - Ancestors

- ID: D000003920

- Term: Diabetes Mellitus

- ID: D000044882

- Term: Glucose Metabolism Disorders

- ID: D000008659

- Term: Metabolic Diseases

- ID: D000004700

- Term: Endocrine System Diseases

- ID: D000006943

- Term: Hyperglycemia

### Condition Browse Module - Browse Branches

- Abbrev: BC18

- Name: Nutritional and Metabolic Diseases

- Abbrev: BC19

- Name: Gland and Hormone Related Diseases

- Abbrev: All

- Name: All Conditions

### Condition Browse Module - Browse Leaves

- ID: M14117

- Name: Prediabetic State

- Relevance: HIGH

- As Found: Prediabetes

- ID: M20295

- Name: Glucose Intolerance

- Relevance: HIGH

- As Found: Prediabetes

- ID: M7115

- Name: Diabetes Mellitus

- Relevance: LOW

- As Found: Unknown

- ID: M11639

- Name: Metabolic Diseases

- Relevance: LOW

- As Found: Unknown

- ID: M25403

- Name: Glucose Metabolism Disorders

- Relevance: LOW

- As Found: Unknown

- ID: M7862

- Name: Endocrine System Diseases

- Relevance: LOW

- As Found: Unknown

- ID: M9994

- Name: Hyperglycemia

- Relevance: LOW

- As Found: Unknown

### Condition Browse Module - Meshes

- ID: D000011236

- Term: Prediabetic State

- ID: D000018149

- Term: Glucose Intolerance

### Intervention Browse Module - Ancestors

- ID: D000097789

- Term: Glucagon-Like Peptide-1 Receptor Agonists

- ID: D000007004

- Term: Hypoglycemic Agents

- ID: D000045505

- Term: Physiological Effects of Drugs

### Intervention Browse Module - Browse Branches

- Abbrev: Gast

- Name: Gastrointestinal Agents

- Abbrev: All

- Name: All Drugs and Chemicals

- Abbrev: Hypo

- Name: Hypoglycemic Agents

### Intervention Browse Module - Browse Leaves

- ID: M9043

- Name: Glucagon

- Relevance: LOW

- As Found: Unknown

- ID: M353561

- Name: Semaglutide

- Relevance: HIGH

- As Found: Physical therapy

- ID: M3401

- Name: Glucagon-Like Peptide-1 Receptor Agonists

- Relevance: LOW

- As Found: Unknown

- ID: M26997

- Name: Glucagon-Like Peptide 1

- Relevance: LOW

- As Found: Unknown

- ID: M10054

- Name: Hypoglycemic Agents

- Relevance: LOW

- As Found: Unknown

### Intervention Browse Module - Meshes

- ID: C000591245

- Term: Semaglutide

### Misc Info Module

- Version Holder: 2024-05-24
